Considerations for managed care pharmacy in evaluating mavacamten, a novel agent for obstructive hypertrophic cardiomyopathy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35199579.
- Also identified by DOI 10.18553/jmcp.2022.28.3.376 and PMC identifier 10372992.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<b>DISCLOSURES:</b> Dr Taddei-Allen was a PRIME Education Moderator on Hypertrophic Cardiomyopathy CE at AMCP Nexus 2021; AJMC article on managed care considerations for hypertrophic cardiomyopathy. No funding was contributed toward the writing of this commentary.
Medical subject headings
- Cardiomyopathy, Hypertrophic
- Pharmacy